Table 3.
Proposed metabolic monitoring protocol
| Assessment | Baseline | 1 month | 2 months | 3 months | 6 months | 9 months | 12 months† |
|---|---|---|---|---|---|---|---|
| Family History (diabetes,high cholesterol, cardiovascular disease, psychiatric history) | x | ||||||
| Risk Factors (smoking, physical activity, screen time, sugar-sweetened beverages) | x | ||||||
| Height | x | x | x | x | x | x | x |
| Weight | x | x | x | x | x | x | x |
| Waist Circumference | x | x | x | x | x | x | x |
| Blood Pressure | x | x | x | x | x | x | x |
| Fasting Plasma Glucose | x | x | x | x | |||
| Fasting Insulin | x | x | x | x | |||
| Fasting Total Cholesterol | x | x | x | x | |||
| Fasting LDL-Cholesterol | x | x | x | x | |||
| Fasting HDL-Cholesterol | x | x | x | x | |||
| Fasting Triglycerides | x | x | x | x | |||
| Aspartate Aminotransferase | x | x | x | x | |||
| Alanine Aminotransferase | x | x | x | x | |||
| Gamma Glutamyltransferase | x | x | x | x | |||
| Prolactin | x | x* | x* | x* | |||
| Amylase‡ | x | x | x | x | |||
| Thyroid Stimulating Hormone‡ | x | x | x |
†
and yearly thereafter or sooner if clinically indicated
*
as clinically indicated [ie. abnormalities in menstruation, galactorrhea/nipple discharge, sexual dysfunction, delays in pubertal development; signs of osteoporosis (fractures)]
‡
quetiapine-treatment only